Last reviewed · How we verify
Soluble beta-glucan (SBG)
Soluble beta-glucan activates innate immune cells to enhance immune response and reduce infection risk.
Soluble beta-glucan activates innate immune cells to enhance immune response and reduce infection risk. Used for Immune support and infection prevention in immunocompromised patients, Adjunctive therapy for respiratory tract infections.
At a glance
| Generic name | Soluble beta-glucan (SBG) |
|---|---|
| Sponsor | Biotec Pharmacon ASA |
| Drug class | Immunostimulant |
| Target | Dectin-1, Complement Receptor 3 (CR3) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Beta-glucans are polysaccharides derived from fungal cell walls that bind to pattern recognition receptors (particularly Dectin-1 and complement receptor 3) on macrophages, neutrophils, and dendritic cells. This binding triggers downstream signaling that enhances phagocytosis, cytokine production, and overall innate immune activation, potentially improving immune defense against infections and supporting immune homeostasis.
Approved indications
- Immune support and infection prevention in immunocompromised patients
- Adjunctive therapy for respiratory tract infections
Common side effects
- Gastrointestinal disturbances
- Mild fever or chills
- Headache
Key clinical trials
- Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors (PHASE1)
- Evaluation of Woulgan in Diabetic Foot Ulcer (PHASE4)
- Effect of SBG in Patients With Breast Cancer (PHASE1, PHASE2)
- Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers (PHASE3)
- Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Soluble beta-glucan (SBG) CI brief — competitive landscape report
- Soluble beta-glucan (SBG) updates RSS · CI watch RSS
- Biotec Pharmacon ASA portfolio CI